Document Type

Article

Publication Date

2009

Publication Title

International Journal of Cancer

Volume

125

Issue

2

Pages

438-445

DOI

10.1002/ijc.24345

Abstract

We have discovered a new, ultrafast therapy for treating skin cancer that is extremely effective with a total electric field exposure time of only 180 mu sec. The application of 300 high-voltage (40 kV/cm), ultrashort (300 nsec) electrical pulses to murine melanomas in vivo triggers both necrosis and apoptosis, resulting in complete tumor remission within an average of 47 days in the 17 animals treated. None of these melanomas recurred during a 4-month period after the initial melanoma had disappeared. These pulses generate small, long-lasting, rectifying nanopores in the plasma membrane of exposed cells, resulting in increased membrane permeability to small molecules and ions, as well as an increase in intracellular Ca2+, DNA fragmentation, disruption of the tumor's blood supply and the initiation of apoptosis. Apoptosis was indicated by a 3-fold increase in Bad labeling and a 72% decrease in Bcl-2 labeling. In addition, microvessel density within the treated tumors fell by 93%. This new therapy utilizing nanosecond pulsed electric fields has the advantages of highly localized targeting of tumor cells and a total exposure time of only 180 psec. These pulses penetrate into the interior of every tumor cell and initiate DNA fragmentation and apoptosis while at the same time reducing blood flow to the tumor. This new physical tumor therapy is drug free, highly localized, uses low energy, has no significant side effects and results in very little scarring.

(C) 2009 UICC

Comments

Web of Science: "Free full-text from publisher -- gold open access."

Original Publication Citation

Nuccitelli, R., Chen, X., Pakhomov, A. G., Baldwin, W. H., Sheikh, S., Pomicter, J. L., . . . Schoenbach, K. H. (2009). A new pulsed electric field therapy for melanoma disrupts the tumor's blood supply and causes complete remission without recurrence. International Journal of Cancer, 125(2), 438-445. doi:10.1002/ijc.24345

ORCID

0000-0002-1089-3194 (Nuccitelli), 0000-0003-2750-0171 (Osgood), 0000-0002-5963-7060 (Swanson), 0000-0002-0434-5001 (Kolb), 0000-0002-6075-9452 (Beebe),

Download

Share

COinS